Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer

NCT02476539 is registered in ClinicalTrials.gov with Tianjin Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT02476539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02476539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 14, 2015
Completion date
September 30, 2023
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast cancer